Search

Home > SurgOnc Today® > 2020 Practice Changing Trials in Sarcoma
Podcast: SurgOnc Today®
Episode:

2020 Practice Changing Trials in Sarcoma
Category: Health
Duration: 00:22:59
Publish Date: 2021-07-29 05:00:00
Description:

Recent trials in sarcoma sought to determine the impact of neoadjuvant therapies and histologic/genomically specific treatments. Valerie Grignol, MD, Gabriel R. Tinoco Suarez, MD, and Alessandro Gronchi, MD, FSSO, discuss the following recent trials will. The EORTC-62902:STRASS trial evaluated the impact of neoadjuvant radiotherapy for retroperitoneal sarcoma on abdominal recurrence-free survival. A study by the Italian, Spanish, French and Polish Sarcoma groups sought to determine if histology-tailored neoadjuvant chemotherapy was superior to standard anthracycline plus ifosfamide for high-risk extremity and trunk soft tissue sarcoma for disease-free and overall survival. The NAVIGATOR study evaluated the PDGFRA inhibitor avapritinib and its activity in D842V-mutant gastrointestinal stromal tumors. Lastly the INVICTUS study evaluated the impact of further line therapy ripretinib, a switch-control tyrosine kinase inhibitor, on progression-free survival in advanced gastrointestinal stromal tumors.

Valerie Grignol, MD - Member, SSO Sarcoma Disease Site Work Group, Assistant Professor of Surgery, The Ohio State University

Gabriel R. Tinoco Suarez, MD - Medical Oncologist and Clinical Assistant Professor - Division of Medical Oncology at The Ohio State University

Alessandro Gronchi, MD, FSSO - Chair Sarcoma Service - Department of Surgery; Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)
Total Play: 0